Featured Research

from universities, journals, and other organizations

Sun-triggered protein drives skin cancer, researchers find

Date:
February 6, 2011
Source:
George Washington University
Summary:
An unexpected immune protein exacerbates cancer due to sun exposure, report researchers. The study suggests that drugs blocking the protein might halt tumor growth in skin cancer patients.

An unexpected immune protein exacerbates cancer due to sun exposure, report researchers in the January 27th issue of Nature. The study suggests that drugs blocking the protein might halt tumor growth in skin cancer patients.

Cutaneous melanoma, an aggressive form of skin cancer, appears to be on the rise. And mortality rates from this difficult-to-treat disease are some of the highest in cancer. Severe sunburns at an early age raise a person's risk of cutaneous melanoma, but the way in which those burns lead to cancer has remained elusive.

In order to discover new ways of treating melanoma, Edward De Fabo, a research professor of in the department of Microbiology, Immunology, and Tropical Medicine at George Washington University Medical Center in Washington, D.C. and a co-corresponding author on the current paper, has been examining the pathway between ultraviolet (UV) rays and melanoma for over a decade. "We ultimately want to figure out what goes wrong so that we can fix it," De Fabo says.

In 2004, he and his collaborators confirmed suspicions that UV-B radiation, as opposed to UV-A, triggered melanoma. And in the current Nature study, they find that UV-B causes white blood cells called macrophages to migrate higher in the skin of mice and release an immune protein, interferon-. Instead of protecting the body like most interferon proteins do, interferon- allowed tumors to grow by preventing the body's natural immune response.

"We didn't expect to see interferon- aiding the tumor, instead of killing cancerous cells," De Fabo says. Interferons, named for the way they interfere with viruses, are traditionally thought to fight tumors. In fact, skin cancer is occasionally treated with another type of interferon, interferon-, but with limited success.

In exposing an unforeseen dark-side of these immune proteins, the report points to a new direction in drug development. Blocking interferon- prevented melanoma cancerous skin cells from growing into tumors in mice. A drug that intercepts interferon-, or its effects, might therefore be used to treat melanoma patients. Indeed, the team found that 70% of cancerous cells from melanoma patients contained high levels of the interferon- protein.

De Fabo and his colleagues made their discovery thanks to a new set of tools, which will aid melanoma researchers for years to come.

At George Washington University, De Fabo developed a high-tech UV radiation device able to shine a precise UV-A or UV-B beam onto several mice simultaneously. Meanwhile, Glenn Marino at the National Cancer Institute in Bethesda, Maryland collaborated with GW researcher Frances Noonan, to engineer mice that could develop the type of melanoma people have, in which cancerous skin cells, or melanoctes, occur near the epidermis. Together, with Raza Zaidi from Merlino's lab, the team made melanocytes glow by labeling them with a green fluorescent protein, so that the hidden cells could be readily extracted from the mice for further experimentation. De Fabo and Noonan's work was supported in part by the National Cancer Institute at the U.S. National Institutes for Health and the Melanoma Research Foundation.

"One real highlight of this study is our unique methodology, both in UV radiation technology and the creation of a mouse melanoma model that resulted from a really neat collaboration," De Fabo says. "These wonderful tools will help melanocyte biology --and hence melanoma studies -- hugely."


Story Source:

The above story is based on materials provided by George Washington University. Note: Materials may be edited for content and length.


Cite This Page:

George Washington University. "Sun-triggered protein drives skin cancer, researchers find." ScienceDaily. ScienceDaily, 6 February 2011. <www.sciencedaily.com/releases/2011/02/110205141314.htm>.
George Washington University. (2011, February 6). Sun-triggered protein drives skin cancer, researchers find. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/02/110205141314.htm
George Washington University. "Sun-triggered protein drives skin cancer, researchers find." ScienceDaily. www.sciencedaily.com/releases/2011/02/110205141314.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins